|
1
|
Mann CD, Neal CP, Garcea G, Manson MM,
Dennison AR and Berry DP: Prognostic molecular markers in
hepatocellular carcinoma: a systematic review. Eur J Cancer.
43:979–992. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sakae M, Kubo S, Takemura S, Sakata C,
Uenishi T, Kodai S, Shinkawa H, Urata Y, Ohata K, Kaneda K,
Nishioka T, Nozawa A and Suehiro S: Effect of interferon therapy on
first and second recurrence after resection of hepatitis c
virus-related hepatocellular carcinoma. Hepatol Res. 42:564–573.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fuks D, Dokmak S, Paradis V, Diouf M,
Durand F and Belghiti J: Benefit of initial resection of
hepatocellular carcinoma followed by transplantation in case of
recurrence: an intention-to-treat analysis. Hepatology. 55:132–140.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barbare JC, Bouche O, Bonnetain F, Raoul
JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A,
Milan C and Bedenne L: Randomized controlled trial of tamoxifen in
advanced hepatocellular carcinoma. J Clin Oncol. 23:4338–4346.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cabrera R and Nelson DR: Review article:
the management of hepatocellular carcinoma. Aliment Pharmacol Ther.
31:461–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kawaoka T, Aikata H, Takaki S, Katamura Y,
Hiramatsu A, Waki K, Takahashi S, Hieda M, Toyota N, Ito K and
Chayama K: Transarterial infusion chemotherapy using
cisplatin-lipiodol suspension with or without embolization for
unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol.
32:687–694. 2009. View Article : Google Scholar
|
|
7
|
Wheatley SP and McNeish IA: Survivin: a
protein with dual roles in mitosis and apoptosis. Int Rev Cytol.
247:35–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Du W and Fan D: Survivin, the
promising target in hepato-cellular carcinoma gene therapy. Cancer
Biol Ther. 7:555–556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baykara M, Akkus M, Yildiz R, Gonul II,
Dursun A, Coskun U, Benekli M, Sevinc A, Dane F and Buyukberber S:
Survivin expression and its potential clinical significance in
gastrointestinal stromal sarcoma. Int Immunopharmacol.
11:2227–2231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodel F, Hoffmann J, Distel L, Herrmann M,
Noisternig T, Papadopoulos T, Sauer R and Rodel C: Survivin as a
radioresistance factor, and prognostic and therapeutic target for
radiotherapy in rectal cancer. Cancer Res. 65:4881–4887. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ito T, Shiraki K, Sugimoto K, Yamanaka T,
Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M,
Nakano T and Suzuki A: Survivin promotes cell proliferation in
human hepatocellular carcinoma. Hepatology. 31:1080–1085. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu WS, Yan HJ, Qin RY, Tian R, Wang M,
Jiang JX, Shen M and Shi CJ: siRNA directed against survivin
enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig
Dis Sci. 54:89–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kami K, Doi R, Koizumi M, Toyoda E, Mori
T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S and Imamura
M: Downregulation of survivin by siRNA diminishes radioresistance
of pancreatic cancer cells. Surgery. 138:299–305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang R, Ma L, Zheng M, Ren J, Wang T,
Meng Y, Zhao J, Jia L, Yao L, Han H, Li K and Yang A: Survivin
knockdown by short hairpin RNA abrogates the growth of human
hepatocellular carcinoma xenografts in nude mice. Cancer Gene Ther.
17:275–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Chen ZD, Du CJ, Xu G and Luo W:
siRNA targeting survivin inhibits growth and induces apoptosis in
human renal clear cell carcinoma 786-O cells. Pathol Res Pract.
205:823–827. 2009. View Article : Google Scholar
|
|
16
|
Guo X, Wang W, Zhou F, Lu Z, Fang R, Jia
F, Bu X, Li R, Zhang B, Wu M and Wei L: siRNA-mediated inhibition
of hTERT enhances chemosensitivity of hepatocellular carcinoma.
Cancer Biol Ther. 7:1555–1560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Altieri DC: New wirings in the survivin
networks. Oncogene. 27:6276–6284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao W, Bao P, Qi H and You H: Resveratrol
down-regulates survivin and induces apoptosis in human
multidrug-resistant SPC-A-1/CDDP cells. Oncol Rep. 23:279–286.
2010.PubMed/NCBI
|
|
20
|
Ryan BM, O’Donovan N and Duffy MJ:
Survivin: a new target for anti-cancer therapy. Cancer Treat Rev.
35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan QZ, Wang CT, Mao YQ, Zhang P, Shi HS,
Li ZY, Pan L, Yu DD, Leng F, Chen X, Ying W, Xu JH, Li W, Wu F, Wen
Y, Ma TT and Wei YQ: Enhanced tumor radiosensitivity by a survivin
dominant-negative mutant. Oncol Rep. 23:97–103. 2010.PubMed/NCBI
|
|
22
|
Dai D, Liang Y, Xie Z, Fu J, Zhang Y and
Zhang Z: Survivin deficiency induces apoptosis and cell cycle
arrest in HepG2 hepatocellular carcinoma cells. Oncol Rep.
27:621–627. 2012.PubMed/NCBI
|
|
23
|
Yang Z, Wang L, Wang H, Shang X, Niu W, Li
J and Wu Y: A novel mimovirus vaccine containing survivin epitope
with adjuvant IL-15 induces long-lasting cellular immunity and high
antitumor efficiency. Mol Immunol. 45:1674–1681. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Couzin J: Breakthrough of the year. Small
RNAs make big splash. Science. 298:2296–2297. 2002.PubMed/NCBI
|
|
25
|
Klenov MS and Gvozdev VA: Heterochromatin
formation: role of short RNAs and DNA methylation. Biochemistry.
70:1187–1198. 2005.PubMed/NCBI
|
|
26
|
Nakahara K and Carthew RW: Expanding roles
for miRNAs and siRNAs in cell regulation. Curr Opin Cell Biol.
16:127–133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nassar A, Lawson D, Cotsonis G and Cohen
C: Survivin and caspase-3 expression in breast cancer: correlation
with prognostic parameters, proliferation, angiogenesis, and
outcome. Appl Immunohistochem Mol Morphol. 16:113–120. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiou SK, Jones MK and Tarnawski AS:
Survivin - an anti-apoptosis protein: its biological roles and
implications for cancer and beyond. Med Sci Monit. 9:PI25–PI29.
2003.PubMed/NCBI
|
|
29
|
Fields AC, Cotsonis G, Sexton D,
Santoianni R and Cohen C: Survivin expression in hepatocellular
carcinoma: correlation with proliferation, prognostic parameters,
and outcome. Mod Pathol. 17:1378–1385. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu H, Chen XP, Zhang WG, Luo SF and Zhang
BX: Expression and significance of new inhibitor of apoptosis
protein survivin in hepatocellular carcinoma. World J
Gastroenterol. 11:3855–3859. 2005.PubMed/NCBI
|
|
31
|
Chen T and Deng C: Inhibitory effect of
siRNA targeting survivin in gastric cancer MGC-803 cells. Int
Immunopharmacol. 8:1006–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu JH, Wang AX, Huang HZ, Wang JG, Pan CB
and Zhang B: Survivin siRNA induces caspase-3-dependent apoptosis
and enhances cisplatin sensitivity in squamous cell carcinoma of
the tongue. Oncol Res. 18:377–385. 2010.PubMed/NCBI
|
